Deraedt Davien, Verfaillie Saartje, Wynants Jokke, Cuppens Kristof
Department of Pulmonology, Sint-Trudo Hospital, Sint-Truiden, Belgium.
Department of Pulmonology and Thoracic Oncology and Jessa and Science, Jessa Hospital, Hasselt, Belgium.
Case Rep Oncol. 2024 Oct 14;17(1):1140-1145. doi: 10.1159/000540861. eCollection 2024 Jan-Dec.
Treatment with topotecan is standard-of-care therapy for relapsed small-cell lung cancer (SCLC). Both oral and intravenous administrations of topotecan have been extensively researched and are found to be equally effective with less adverse events in the oral group.
We report a case of a patient with SCLC, who had previously received oral topotecan, with radiological stable disease with no changes in tumor or metastasis diameter size after two administrations. Subsequently, this patient received intravenous topotecan instead of oral due to supply difficulties. After one administration of intravenous topotecan, we saw significant disease regression.
This is to our knowledge the first reported case of better response of intravenous topotecan than oral topotecan. Multiple extrinsic (e.g., food, medication) factors were investigated but could not deliver an explanation.
拓扑替康治疗是复发性小细胞肺癌（SCLC）的标准治疗方法。拓扑替康的口服和静脉给药均已得到广泛研究，发现二者疗效相当，且口服组不良事件较少。
我们报告一例SCLC患者，该患者此前接受口服拓扑替康治疗，两次给药后影像学检查显示疾病稳定，肿瘤及转移灶直径大小无变化。随后，由于供应困难，该患者改为接受静脉拓扑替康治疗。静脉注射拓扑替康一次后，我们观察到疾病显著消退。
据我们所知，这是首例报道的静脉拓扑替康比口服拓扑替康反应更好的病例。我们研究了多种外在因素（如食物、药物），但未能给出解释。
